The very enzyme that is associated with increased covid-19 mortality is blocked by an ANTI-VENOM compound
The American Society for Clinical Investigation published research investigating the biochemical properties of plasma taken from deceased covid-19 patients. The team of researchers wanted to “identify the cellular and molecular mechanisms responsible for severe COVID-19 that led to death.” Patients with severe covid-19 showed mitochondrial dysfunction and elevated metabolites associated with secreted phospholipase A2 (sPLA2) activity. This is the same enzyme that is elevated after a venomous snake bite. Could this increase in sPLA2 be the body’s natural reaction to infection, or could it be an indicator that the body is infected/poisoned by something more nefarious — perhaps venomous particles?
“Deceased COVID-19 patients had higher levels of circulating, catalytically active sPLA2 group IIA (sPLA2-IIA), with a median value that was 9.6-fold higher than that for patients with mild disease and 5.0-fold higher than the median value for survivors of severe COVID-19,” the study authors wrote.
Anti-venom compound being studied to help patients with severe covid-19 disease
According to years of biochemical research, a broad-spectrum ANTI-VENOM compound inhibits the very enzyme that is associated with severe covid-19 disease and covid-19 mortality. It turns out that this enzyme (sPLA2) is inhibited by an anti-venom compound called varespladib. Clinical trials show that varespladib is a potent inhibitor of secretory phospholipase A2 (sPLA2). Varespladib has demonstrated improvements in cardiovascular risks, including a reduction in inflammatory C-reactive proteins and a near complete suppression of the target enzyme, sPLA2.
A Medscape article from November 2020 concurred that the lung inflammation caused by covid-19 produces the sPLA2 enzyme. The article also said a more deadly version of the same enzyme is produced by SNAKE VENOM. Researchers are using varespladib as a broad-spectrum, anti-venom drug because it targets this same sPLA2 enzyme. Researchers also want to deploy the anti-venom compound against severe covid-19 cases.
This brings up the question: Could the clinical manifestation of “covid-19” actually be the ill effects of a bioweapon that contains properties from snake venom? This may explain why severe covid patients and those vaccinated with the spike protein mRNA may suffer from dizziness, paralysis, coagulated blood and inflamed lungs. These are all similar symptoms from a venomous snake bite [Figure 6]. If severe covid-19 involves an enzyme that can be suppressed by anti-venom, does the actual SARS-CoV-2 contain genetic code from snake venom?